Pulmonary hypertension: Hemodynamic evaluation;Pulmonale Hypertonie: Invasive Diagnostik

Deutsche Medizinische Wochenschrift

Volumn 135, Issue SUPPL. 3, 2010, Pages

  Opitz, Christian F ^a   Blindt, R ^b   Blumberg, F ^c   Borst, M M ^d   Bruch, L ^e   Leuchte, H ^f   Nagel, C ^g   Peters, K ^h   Rosenkranz, S ⁱ   Schranz, D ^j   Skowasch, D ^k   Lichtblau, M ^g   Tiede, H ^l   Weil, J ^m   Ewert, R ⁿ  

^a German Red Cross Hospital   (Germany)

^b Kardio Nord   (Germany)

^c PROSPER HOSPITAL   (Germany)

^d CARITAS KRANKENHAUS   (Germany)

^e Klinik fur Innere Medizin   (Germany)

^f Krankenhaus Neuwittelsbach   (Germany)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h Herzzentrum Bad Krozingen ^*  (Germany)

ⁱ UNIVERSITY OF COLOGNE   (Germany)

^j JUSTUS LIEBIG UNIVERSITY   (Germany)

^k UNIVERSITY HOSPITAL BONN   (Germany)

^l UNIVERSITY HOSPITAL GIESSEN   (Germany)

^m UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁿ UNIVERSITY OF GREIFSWALD   (Germany)

more..

Author keywords

diagnosis; guidelines; pulmonary hypertension; right heart catheterization; vasoreactivity testing

Indexed keywords

ILOPROST; DIAGNOSTIC AGENT; VASODILATOR AGENT;

CONFERENCE PAPER; EVALUATION; HUMAN; HYPOXIA; LUNG CAPILLARY; LUNG HEMODYNAMICS; MORBIDITY; MORTALITY; PROGNOSIS; PULMONARY HYPERTENSION; SENSITIVITY AND SPECIFICITY; SYMPTOM; VASODILATATION; CHILD; CONSENSUS DEVELOPMENT; DRUG EFFECT; EVIDENCE BASED MEDICINE; GERMANY; HEMODYNAMICS; INHALATIONAL DRUG ADMINISTRATION; LUNG WEDGE PRESSURE; PATHOPHYSIOLOGY; PHYSIOLOGY; PRACTICE GUIDELINE; SWAN GANZ CATHETER; VASCULAR RESISTANCE;

ADMINISTRATION, INHALATION; CATHETERIZATION, SWAN-GANZ; CHILD; EVIDENCE-BASED MEDICINE; GERMANY; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; PULMONARY WEDGE PRESSURE; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 77957337725     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0030-1263315     Document Type: Conference Paper

References (39)

1. Humbert M, Sitbon O, Chaouat A et al. Pulmonary Arterial Hypertension in France: Results from a National Registry. Am J Crit Care Med 2006 173 1023-1030
2. Peacock A J., Murphy N F., McMurray J J., Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007 30 104-109 (Pubitemid 47074013)
3. Dalonzo G E., Barst R J., Ayres S M. et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991 115 343-349
4. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009 34 888-894
5. Naeije R, Melot C, Niset G, Delcroix M, Wagner P D. Mechanisms of improved arterial oxygenation after peripheral chemoreceptor stimulation during hypoxic exercise. J Appl Physiol 1993 74 1666-1671 (Pubitemid 23133457)
6. Hoeper M M., Lee S H., Voswinckel R et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006 48 2546-2552 (Pubitemid 44881214)
7. Rich S, Kaufmann E, Levy P S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992 327 76-81
8. Sitbon O, Humbert M, Jais X et al. Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension. Circulation 2005 111 3105-3111 (Pubitemid 40847788)
9. Galie N, Ussia G, Passarelli P et al. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol 1995 75 55A-62A
10. McLaughlin V V., Genthner D E., Panella M M., Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998 338 273-277 (Pubitemid 28065252)
11. Jing Z C., Jiang X, Han Z Y. et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J 2009 33 1354-1360
12. Opitz C F., Rubin L J. Acute vasodilator testing in idiopathic pulmonary arterial hypertension: must we take NO for the answer? Eur Respir J 2009 33 1247-1249
13. Hoeper M M., Ghofrani H A., Gorenflo M et al. Diagnostik und Therapie der pulmonalen Hypertonie: Europäische Leitlinie 2009. Pneumologie 2010 64 401-414
14. Tonelli A R., Alnuaimat H, Mubarak K. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respir Med 2010 104 481-496
15. Thenappan T, Shah S J., Rich S et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010 35 1079-1087
16. Higenbottam T, Butt A Y., McMahon A, Westerbeck R, Sharples L. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998 80 151-155 (Pubitemid 28389476)
17. Wensel R, Opitz C F., Anker S D. et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002 106 319-324 (Pubitemid 34778955)
18. Thabut G, Dauriat G, Stern J B. et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005 127 1531-1536 (Pubitemid 46218776)
19. Sitbon O, Humbert M, Nunes H et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am CollCardiol 2002 40 780-788 (Pubitemid 34925627)
20. Sitbon O, McLaughlin V V., Badesch D B. et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005 60 1025-1030 (Pubitemid 41705471)
21. McLaughlin V V., Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002 106 1477-1482
22. McLaughlin V V., Sitbon O, Badesch D B. et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005 25 244-249 (Pubitemid 40246523)
23. Castelain V, Chemla D, Humbert M et al. Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension. Am J Respir Crit Care Med 2002 165 338-340 (Pubitemid 34118505)
24. Blumberg F C., Riegger G A., Pfeifer M. Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise. Chest 2002 121 1566-1571 (Pubitemid 34499672)
25. Zimmermann R, Kreuder J, Michel-Behnke I, Voelkel N F., Schranz D. Pulmonary flow reserve in children with idiopathic pulmonary arterial hypertension: implications for diagnosis and therapy. Eur J Med Res 2006 11 208-213 (Pubitemid 43750526)
26. Gorenflo M, Bettendorf M, Brockmeier K, Ulmer H E. Pulmonary vasoreactivity and vasoactive mediators in children with pulmonary hypertension. ZKardiol 2000 89 1000-1008 (Pubitemid 30450362)
27. Raffy O, Azarian R, Brenot F et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation 1996 93 484-488 (Pubitemid 126425249)
28. Halpern S D., Taichman D B. Misclassification of Pulmonary Hypertension Due to Reliance on Pulmonary Capillary Wedge Pressure Rather Than Left-Ventricular End-Diastolic Pressure. Chest 2009 136 37-43
29. Natale M E., Pina I L. Evaluation of pulmonary hypertension in heart transplant candidates. Curr Opin Cardiol 2003 18 136-140
30. Delgado J F., Gomez-Sanchez M A., Saenz de la Calzada C et al. Impact of mild pulmonary hypertension on mortality and pulmonary artery pressure profile after heart transplantation. J Heart Lung Transplant 2001 20 942-948 (Pubitemid 32824139)
31. Sablotzki A, Czeslick E, Gruenig E et al. First experiences with the stable prostacyclin analog iloprost in the evaluation of heart transplant candidates with increased pulmonary vascular resistance. J Thorac Cardiovasc Surg 2003 125 960-962 (Pubitemid 36457524)
32. Lepore J J., Maroo A, Pereira N L. et al. Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 2002 90 677-680 (Pubitemid 35264557)
33. von Scheidt W, Costard-Jaeckle A, Stempfle H U. et al. Prostaglandin E1 testing in heart failure-associated pulmonary hypertension enables transplantation: the PROPHET study. J Heart Lung Transplant 2006 25 1070-1076 (Pubitemid 44322050)
34. Bonderman et al. A non-invasive algorithm to exclude precapillary pulmonary hypertension. Eur Resp J 2010 erj00896-2010; published ahead of print 2010
35. Oliveira E C., Ribero A L., Amaral C F. Adenosine for vasoreactivity testing in pulmonary hypertension: a head-to-head comparison with inhaled nitric oxide. Respir Med 2010 104 606-611
36. Bundesärztekammer. Richtlinie zur Organtransplantation gemäß 16 Transplantationsgesetz. Dtsch Arztebl 2000 97 A-396 / B-333 / C-310
37. Galie N, Hoeper M M., Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J 2009 34 1219-1263
38. Galie N, Hoeper M M., Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009 30 2493-2537
39. Hoeper M M., Ghofrani H A., Gorenflo M et al. Diagnostik und Therapie der pulmonalen Hypertonie: Europäische Leitlinie 2009. Pneumologie 2010 64 401-414